The FDA has signed a new confidentiality agreement with the European Commission (EC) and the European Medicines Agency (EMA). The agreement will allow the FDA to share with the EC and EMA nonpublic, commercially confidential information (including trade secrets) related to inspections.
The FDA has signed a new confidentiality agreement with the European Commission (EC) and the European Medicines Agency (EMA). The agreement will allow the FDA to share with the EC and EMA nonpublic, commercially confidential information (including trade secrets) related to inspections.
FDA commissioner, Scott Gottlieb, MD, took to Twitter to hail the aggreement, saying that it would lead to more efficient manufacturing site inspections:
The FDA has maintained confidentiality agreements with European regulators since 2003, which have allowed for the exchange of information as part of the regulatory and scientific process. However, the FDA could not, under previous arrangements, share full inspection reports.
The EC’s directorate general certified that neither it nor the EMA would disclose to the public any confidential, personal, law enforcement, national security, or pre-decision information shared in confidence. The European agencies may, however, share information received from the FDA with the regulatory agencies of individual EU member states, but only if those states have made prior arrangements with the FDA. The FDA also assured the European Union’s (EU) agencies that it would take all necessary steps to prevent confidential information from being publicly disclosed.
The new agreement is part of a larger plan regarding mutual recognition of inspections. The plan, designed to reduce duplication of efforts, allows US and EU regulators to rely on one another’s inspection reports on good manufacturing practices in their own territories. As of a March agreement to mutually recognize inspections of manufacturing facilities on both sides of the Atlantic, European inspections of US facilities, and vice versa, are limited to “exceptional circumstances.”
The respective agencies, which have comparable regulatory and procedural frameworks for the inspection of facilities, hope that the overall plan will allow regulators to make better use of their resources. The EU already uses mutual recognition frameworks with other regulatory agencies, such as those located in Australia, New Zealand, Canada, Japan, and Switzerland.
In preparation for an agreement with the United States, the EU invited the FDA to observe the EU’s Joint Audit Programme, a framework in which 2 EU member states audit the regulatory agency of another member state. FDA observed the audit of Sweden’s inspectorate by the United Kingdom and Norway, and observed an additional 13 audits before solidifying its own agreement with the EU.
The FDA’s associate commissioner for global regulatory policy, Dara Corrigan, called the March mutual recognition agreement “an important step in working collaboratively and strategically with key partners to help ensure that American patients have access to safe, effective and high-quality drugs.”
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
2 Commerce Drive
Cranbury, NJ 08512